Chapter 9. Green Processes for Peptide Mimetic Diabetic Drugs

  1. Dr. Peter J. Dunn2,3,
  2. Dr. Andrew S. Wells4 and
  3. Dr. Michael T. Williams5
  1. Yasuhiro Sawai and
  2. Mitsuhisa Yamano

Published Online: 19 MAR 2010

DOI: 10.1002/9783527629688.ch9

Green Chemistry in the Pharmaceutical Industry

Green Chemistry in the Pharmaceutical Industry

How to Cite

Sawai, Y. and Yamano, M. (2010) Green Processes for Peptide Mimetic Diabetic Drugs, in Green Chemistry in the Pharmaceutical Industry (eds P. J. Dunn, A. S. Wells and M. T. Williams), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527629688.ch9

Editor Information

  1. 2

    Pfizer Green Chemistry Lead, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

  2. 3

    Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK

  3. 4

    Astra Zeneca, Process Research & Development, Bakewell Road, Loughborough, LE11 5RH, United Kingdom

  4. 5

    CMC Consultant, 133, London Road, Deal, Kent, CT14 9TY, United Kingdom

Author Information

  1. Takeda Pharmaceutical Company Ltd., Chemical Development Laboratories, 17-85 Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan

Publication History

  1. Published Online: 19 MAR 2010
  2. Published Print: 10 MAR 2010

ISBN Information

Print ISBN: 9783527324187

Online ISBN: 9783527629688

SEARCH

Keywords:

  • peptide-like drugs;
  • unnatural amino acids;
  • optical resolution;
  • diastereomeric salt;
  • amorphous API;
  • cation exchange chromatography;
  • chrystallization-induced diastereomer transformation

Summary

This chapter contains sections titled:

  • Introduction

  • Green Chemistry Considerations in Peptide-like API Manufacture

  • Purification Process to Manufacture Amorphous API

  • Preparation of Unnatural Amino Acids

  • Summary

  • Acknowledgments

  • References